Spots Global Cancer Trial Database for temsirolimus
Every month we try and update this database with for temsirolimus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT01375829 | Adult Solid Neo... | Ixabepilone Pharmacological... Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | NCT02567435 | Alveolar Rhabdo... Botryoid-Type E... Embryonal Rhabd... Rhabdomyosarcom... Sclerosing Rhab... Spindle Cell Rh... | Cyclophosphamid... Dactinomycin Irinotecan Hydr... Laboratory Biom... Questionnaire A... Radiation Thera... Temsirolimus Vincristine Sul... Vinorelbine | - 40 Years | National Cancer Institute (NCI) | |
| A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | NCT01396408 | Advanced Rare T... | Sunitinib Temsirolimus | 16 Years - | Canadian Cancer Trials Group | |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | NCT00782275 | Renal Cell Carc... Kidney Cancer | bevacizumab temsirolimus | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies | NCT00703170 | Resistant Solid... | Temsirolimus Pegylated lipos... | 18 Years - | Washington University School of Medicine | |
| Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | NCT01180049 | Non-Hodgkin's L... | temsirolimus temsirolimus | 18 Years - | Pfizer | |
| Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery | NCT01206140 | Recurrent Adult... Stage III Adult... Stage IV Adult ... | Laboratory Biom... Selumetinib Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer | NCT01025453 | Thyroid Cancer | Temsirolimus an... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma | NCT01222715 | Adult Rhabdomyo... Childhood Alveo... Childhood Pleom... Childhood Rhabd... Previously Trea... Recurrent Adult... Recurrent Child... | Bevacizumab Cyclophosphamid... Laboratory Biom... Temsirolimus Vinorelbine Tar... | - 29 Years | National Cancer Institute (NCI) | |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | NCT01381692 | Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... | Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| CCI-779 in Treating Patients With Advanced Solid Tumors | NCT00003712 | Brain and Centr... Metastatic Canc... Unspecified Adu... | temsirolimus | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Study of Temsirolimus, Topotecan, and Bortezomib | NCT00770731 | Advanced Cancer | Torisel (Temsir... Hycamtin (Topot... Velcade (Bortez... | - | M.D. Anderson Cancer Center | |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | NCT01065662 | Endometrial Can... Ovarian Cancer Cervical Cancer Fallopian Tube ... Peritoneal Canc... | temsirolimus cediranib | 18 Years - | Dana-Farber Cancer Institute | |
| Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors | NCT01141244 | Unspecified Chi... | temsirolimus temozolomide irinotecan hydr... laboratory biom... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00112476 | Recurrent Melan... Recurrent Renal... Stage IV Melano... Stage IV Renal ... Unspecified Adu... | bryostatin 1 temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | NCT00980460 | PRETEXT I Hepat... PRETEXT II Hepa... PRETEXT III Hep... PRETEXT IV Hepa... | Cisplatin Dexrazoxane Doxorubicin Hyd... Fluorouracil Irinotecan Hydr... Laboratory Biom... Liver Transplan... Temsirolimus Therapeutic Con... Vincristine Sul... | - 21 Years | National Cancer Institute (NCI) | |
| Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | NCT00483262 | Multiple Myelom... | CCI-779 Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00109967 | Recurrent Mantl... | rituximab temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan | NCT02776644 | Renal Cell Carc... | - | Pfizer | ||
| Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | NCT00998036 | Triple Negative... | Temsirolimus Cisplatin Erlotinib | 18 Years - | Columbia University | |
| Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | NCT05773326 | High Grade Glio... Glioma Glioma, Maligna... Glioblastoma | Temsirolimus | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| Temsirolimus as Second-line Therapy in HCC | NCT01567930 | Unresectable or... | Temsirolimus | 18 Years - | University of Tennessee Cancer Institute | |
| Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer | NCT00593060 | Colorectal Canc... Colorectal Aden... | Temsirolimus Cetuximab | 18 Years - | Massachusetts General Hospital | |
| Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | NCT01078142 | Follicular Lymp... Mantle Cell Lym... | Temsirolimus, R... | 18 Years - | Johannes Gutenberg University Mainz | |
| Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer | NCT01196429 | Ovarian Clear C... Stage III Ovari... Stage IV Ovaria... | Carboplatin Docetaxel Laboratory Biom... Paclitaxel Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | NCT02423954 | Advanced Cancer Pancreatic Canc... Renal Cell Canc... Non Small Cell ... Colorectal Carc... Endometrial Uterine | Temsirolimus Irinotecan Irinotecan + ca... nivolumab | 18 Years - | Western Regional Medical Center | |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer | NCT00678769 | Malignant Neopl... | Cixutumumab Laboratory Biom... Pharmacological... Temsirolimus | 16 Years - | National Cancer Institute (NCI) | |
| STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma | NCT01653067 | Diffuse Large B... | Rituximab, Tems... | 18 Years - | University Hospital Heidelberg | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma | NCT01016015 | Metastatic Oste... Recurrent Adult... Recurrent Osteo... Stage III Adult... Stage IV Adult ... | Cixutumumab Laboratory Biom... Temsirolimus | 16 Years - | National Cancer Institute (NCI) | |
| CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors | NCT00098501 | Unspecified Adu... | pelitinib temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus and Radiation for Non-Small Cell Lung Cancer | NCT00796796 | Carcinoma, Non-... | Temsirolimus Radiation thera... | 18 Years - | Washington University School of Medicine | |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery | NCT00281957 | Recurrent Melan... Stage IV Melano... | sorafenib tosyl... tipifarnib temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus in Myelodysplastic Syndrome (MDS) | NCT01111448 | Myelodysplastic... | Temsirolimus | 18 Years - | Technische Universität Dresden | |
| Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | NCT00398515 | Refractory Mult... Stage II Multip... Stage III Multi... | lenalidomide temsirolimus pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | NCT01010126 | Adult Hepatocel... Advanced Adult ... Endometrial Ser... Localized Non-R... Lung Carcinoid ... Malignant Pancr... Malignant Pancr... Malignant Pancr... Malignant Pancr... Metastatic Dige... Ovarian Carcino... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Pancreatic Alph... Pancreatic Beta... Pancreatic Delt... Pancreatic G-Ce... Pancreatic Poly... Recurrent Adult... Recurrent Diges... Recurrent Fallo... Recurrent Ovari... Recurrent Pancr... Recurrent Prima... Recurrent Uteri... Regional Digest... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino... | Bevacizumab Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT01851408 | Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano... | sorafenib tosyl... temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | NCT03203525 | Advanced Malign... Colorectal Carc... Metastatic Mali... Refractory Mali... | Bevacizumab Fluorouracil Leucovorin Oxaliplatin Pegylated Lipos... Temsirolimus Tumor Treating ... | 18 Years - | M.D. Anderson Cancer Center | |
| Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer | NCT01827267 | HER2-mutant Non... | neratinib temsirolimus | 18 Years - | Puma Biotechnology, Inc. | |
| Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | NCT01687673 | Hepatocellular ... | Temsirolimus Sorafenib: | 18 Years - 85 Years | University of California, San Francisco | |
| CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS) | NCT01206036 | Prostatic Neopl... | Docetaxel Temsirolimus | 18 Years - | Central European Society for Anticancer Drug Research | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Temsirolimus and Radiation for Non-Small Cell Lung Cancer | NCT00796796 | Carcinoma, Non-... | Temsirolimus Radiation thera... | 18 Years - | Washington University School of Medicine | |
| Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | NCT02446431 | Solid Tumor | Bevacizumab Cyclophosphamid... Valproic Acid Temsirolimus | 12 Months - 31 Years | Miller Children's & Women's Hospital Long Beach | |
| Efficacy Study of Temsirolimus to Treat Head and Neck Cancer | NCT01172769 | Head and Neck S... | Temsirolimus | 18 Years - | Hannover Medical School | |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | NCT01166126 | Mucosal Melanom... Recurrent Melan... Stage IV Melano... | temsirolimus selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | NCT00782275 | Renal Cell Carc... Kidney Cancer | bevacizumab temsirolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | NCT00998036 | Triple Negative... | Temsirolimus Cisplatin Erlotinib | 18 Years - | Columbia University | |
| Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis | NCT01079767 | Liver Cancer | temsirolimus | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | NCT01180049 | Non-Hodgkin's L... | temsirolimus temsirolimus | 18 Years - | Pfizer | |
| Temsirolimus in Combination With Metformin in Patients With Advanced Cancers | NCT01529593 | Advanced Cancer... | Temsirolimus Metformin | 14 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | NCT01646021 | Mantle Cell Lym... | Ibrutinib Temsirolimus | 18 Years - | Janssen Research & Development, LLC | |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | NCT01187199 | Advanced Cancer | Temsirolimus Bevacizumab Paclitaxel Sorafenib Carboplatin | - | M.D. Anderson Cancer Center | |
| Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer | NCT01827943 | Relapsed Bladde... | Temsirolimus | 18 Years - | Institut Bergonié | |
| Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck | NCT00195299 | Squamous Cell C... | Temsirolimus | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00699491 | Male Breast Car... Recurrent Breas... Stage IV Breast... | Cixutumumab Laboratory Biom... Pharmacological... Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT00349206 | Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano... | sorafenib tosyl... temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer | NCT00376688 | Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Laboratory Biom... Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | NCT01020305 | Prostate Cancer Prostatic Neopl... Castrate-resist... Androgen-insens... Hormone-refract... Metastatic Dise... | Temsirolimus Casodex (bicalu... | 18 Years - | Stanford University | |
| CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00016328 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | temsirolimus laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT01155258 | Extensive Stage... Hereditary Para... Male Breast Can... Malignant Parag... Metastatic Gast... Metastatic Pheo... Pancreatic Poly... Recurrent Breas... Recurrent Cervi... Recurrent Endom... Recurrent Gastr... Recurrent Islet... Recurrent Neuro... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pheoc... Recurrent Prost... Recurrent Renal... Recurrent Small... Recurrent Uteri... Regional Gastro... Regional Pheoch... Stage III Cervi... Stage III Endom... Stage III Neuro... Stage III Ovari... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Uteri... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Endome... Stage IV Neuroe... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Uterin... Stage IVA Cervi... Stage IVB Cervi... Thyroid Gland M... | temsirolimus vinorelbine dit... | 18 Years - | University of Southern California | |
| Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | NCT01078142 | Follicular Lymp... Mantle Cell Lym... | Temsirolimus, R... | 18 Years - | Johannes Gutenberg University Mainz | |
| Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma | NCT00397982 | Recurrent Melan... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... | Bevacizumab Laboratory Biom... Temsirolimus Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | NCT01111825 | Breast Cancer | Temsirolimus Neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Tumor Registry of Advanced Renal Cell Carcinoma | NCT00610012 | Renal Cell Carc... | 18 Years - | iOMEDICO AG | ||
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | NCT00093782 | Metastatic Gast... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... | temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT01155258 | Extensive Stage... Hereditary Para... Male Breast Can... Malignant Parag... Metastatic Gast... Metastatic Pheo... Pancreatic Poly... Recurrent Breas... Recurrent Cervi... Recurrent Endom... Recurrent Gastr... Recurrent Islet... Recurrent Neuro... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pheoc... Recurrent Prost... Recurrent Renal... Recurrent Small... Recurrent Uteri... Regional Gastro... Regional Pheoch... Stage III Cervi... Stage III Endom... Stage III Neuro... Stage III Ovari... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Uteri... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Endome... Stage IV Neuroe... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Uterin... Stage IVA Cervi... Stage IVB Cervi... Thyroid Gland M... | temsirolimus vinorelbine dit... | 18 Years - | University of Southern California | |
| Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | NCT00112736 | Adult Anaplasti... Adult Anaplasti... Adult Diffuse A... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Pilocytic... Adult Pineal Gl... Adult Subependy... Recurrent Adult... | erlotinib temsirolimus therapeutic con... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00016328 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | temsirolimus laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
